SELECT研究：EGFR突變NSCLC術(shù)后厄羅替尼輔助治療

SELECT演示數(shù)據(jù)演示數(shù)據(jù)演示數(shù)據(jù)演示數(shù)據(jù)演示數(shù)據(jù)演EGFR演示NSCLC演示數(shù)據(jù)演示數(shù)據(jù)演示數(shù)據(jù)演示數(shù)據(jù)演示數(shù)，演示數(shù)據(jù)演示數(shù)據(jù)1。

2008演1演示2012演5演示，100演NSCLC演示數(shù)據(jù)，演示IA演13%，IB演32%，IIA演11%，IIB演16%，IIIA演28%，演示1，演示數(shù)據(jù)演示數(shù)據(jù)演示數(shù)據(jù)演示數(shù)據(jù)，演示數(shù)據(jù)演150 mg演示數(shù)據(jù)演示 2演。69%演示數(shù)據(jù)演示數(shù)據(jù)演示數(shù)據(jù)演示數(shù)據(jù)演示數(shù)，演示數(shù)據(jù)4演示5演示數(shù)據(jù)演，40%演示數(shù)據(jù)演示100mg演示數(shù)據(jù)，16%演示數(shù)據(jù)演示50mg演示數(shù)據(jù)。